Evidence map›Paper›PMID 30740245›Full record

ArticleMolecular systems design & engineering2018

Nitro Sulfonyl Fluorides are a new pharmacophore for the development of antibiotics.

Corinne Sadlowski, Bora Park, Clarissa Araújo, Subhamoy Das, D Lucas Kerr, Maomao He, Hesong Han, Lee Riley, Niren Murthy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular systems design & engineering, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Diversity Oriented Clicking for Modular Synthesis.Nature reviews. Methods primers · 2025
    Article
  2. Review
  3. SuFEx-enabled, agnostic discovery of covalent inhibitors of human neutrophil elastase.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Corinne SadlowskiDepartment of Bioengineering, University of California, Berkeley, California, 94720, USA.
Bora ParkDepartment of Bioengineering, University of California, Berkeley, California, 94720, USA.
Clarissa AraújoDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, California, 94720, USA.
Subhamoy DasDepartment of Bioengineering, University of California, Berkeley, California, 94720, USA.
D Lucas KerrDepartment of Bioengineering, University of California, Berkeley, California, 94720, USA.
Maomao HeDepartment of Bioengineering, University of California, Berkeley, California, 94720, USA.
Hesong HanDepartment of Bioengineering, University of California, Berkeley, California, 94720, USA.
Lee RileyDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, California, 94720, USA.
Niren MurthyDepartment of Bioengineering, University of California, Berkeley, California, 94720, USA.

Funding

Consortium for drug-resistant Gram-negative pathogen detectionR01AI117064 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI LEE, LUKE P., MURTHY, NIREN · 2015 to 2019
$5.7M
18F Conjugated Maltodextrins for the Detection of Medical Device InfectionsR01EB020008 · NIBIB · EMORY UNIVERSITY · PI GOODMAN, MARK MYRON, MURTHY, NIREN · 2015 to 2018
$2.4M
Treatment of Duchenne Muscular Dystrophy with Cas9 Protein Complexed to Gold NanoparticlesR01EB023776 · NIBIB · UNIVERSITY OF CALIFORNIA BERKELEY · PI CONBOY, IRINA M, MURTHY, NIREN · 2017 to 2020
$1.4M
Maltose Targeted AntibioticsR33AI119115 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI MURTHY, NIREN, RILEY, LEE W · 2017 to 2019
$1.4M
Maltose Targeted AntibioticsR21AI119115 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI MURTHY, NIREN, RILEY, LEE W · 2015 to 2016
$414k
NIAID NIH HHS R01 AI117064NIAID NIH HHS R21 AI119115NIAID NIH HHS R33 AI119115NIBIB NIH HHS R01 EB020008NIBIB NIH HHS R01 EB023776
6 · The paper itself

Abstract

The development of antibiotics against Gram-negative bacteria is a central problem in drug discovery. In this report, we demonstrate that aromatic sulfonyl fluorides with a nitro group in their ortho position have remarkable antibacterial activity and are active against drug-resistant pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), multidrug resistant Acinetobacter baumannii, and Pseudomonas aeruginosa.

Identifiers

PMID30740245
PMCPMC6366622

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.